RELATING TO HUMAN SERVICES -- MEDICAL ASSISTANCE -- PRESCRIPTION, DRUGS
Summary
H7587 would amend Rhode Island’s medical assistance prescription drug law to bar the Medicaid program, and any managed care organization contracting with it, from requiring prior authorization or step therapy for drugs classified as anticonvulsants or antipsychotics. The bill is aimed at improving access to these medications for enrollees who need them, while still allowing clinical prior authorization edits and preserving the ability to deny drugs that have been removed from the market for safety reasons.
The bill also requires the medical assistance program and its managed care partners to collect and report detailed utilization and spending data on anticonvulsant and antipsychotic medications for years 2021 through 2029, including claims, rebates, preferred drug list adherence, prior authorization activity, step therapy exceptions, and generic utilization. In addition, the Department of Health must compile data on mental health emergency-related spending by the state and each municipality across ambulance, hospital, police, and fire services, and the Executive Office of Health and Human Services must submit the compiled reports to legislative leaders and committees by October 1, 2029. The act would apply to policies and contracts beginning January 1, 2027, and would sunset on December 31, 2029.
Impact
This bill would create a new statutory restriction in chapter 40-21 of the General Laws limiting utilization management tools for Medicaid-covered anticonvulsant and antipsychotic medications. It would require the Rhode Island medical assistance program to revise current and future managed care contracts to comply, potentially affecting pharmacy benefit administration, managed care operations, and coverage determinations for Medicaid enrollees. The reporting requirements would also impose new data collection obligations on the executive branch and municipalities, but the law is temporary and would be repealed at the end of 2029.
Sentiment
No committee transcripts or recorded votes were provided, so there is no direct evidence of debate or formal support/opposition in the available record. Based on the bill’s sponsor list and subject matter, the measure appears to reflect a policy interest in reducing barriers to mental health and seizure-disorder medications for Medicaid beneficiaries. The inclusion of detailed reporting and a sunset suggests an effort to balance access concerns with oversight and evaluation.
Contention
The main policy tension in the bill is between improving medication access and preserving managed care cost-control tools. Supporters would likely favor eliminating prior authorization and step therapy for anticonvulsants and antipsychotics because those requirements can delay treatment or disrupt continuity of care. Potential opponents or skeptics may be concerned about increased program costs, reduced formulary management flexibility, and the administrative burden of the extensive reporting requirements. The bill’s exceptions for clinical edits and FDA safety removals appear designed to address some of those concerns.